Dr. Reddy’s to Announce Q1 FY27 Results and Host Earnings Call on July 22, 2026
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).
Dr. Reddy’s Laboratories announced on July 13, 2026 that it will release its financial results for the quarter ended June 30, 2026 (Q1 FY27) on Wednesday, July 22, 2026, following a meeting of its board of directors. The company plans to disseminate the results across stock exchanges, media and its website, with a press presentation also to be made available online.
Management will host an earnings call on July 22, 2026 at 19:30 IST / 10:00 ET to discuss the quarterly performance with investors and analysts. An audio recording and transcript of the call will subsequently be posted on the company’s website, underlining Dr. Reddy’s efforts to maintain regular and transparent communication with capital-market stakeholders around its quarterly earnings cycle.
The most recent analyst rating on (RDY) stock is a Buy
with a $1540.00 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana, with listings on the BSE, NSE, NYSE and NSE IFSC. It develops, manufactures and markets generic and branded formulations as well as active pharmaceutical ingredients, serving regulated markets worldwide with a focus on affordable medicines.
Average Trading Volume: 2,659,440
Technical Sentiment Signal: Buy
Current Market Cap: $10.87B
See more data about RDY stock on TipRanks’ Stock Analysis page.
